A5088550663- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- melanin and skin pigmentation
- Synthesis and biological activity
- Quinazolinone synthesis and applications
- CAR-T cell therapy research
- Brain Metastases and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cell Adhesion Molecules Research
- Cancer Immunotherapy and Biomarkers
- Skin Protection and Aging
- AI in cancer detection
- S100 Proteins and Annexins
- Cancer-related Molecular Pathways
- Nonmelanoma Skin Cancer Studies
- Toxin Mechanisms and Immunotoxins
- Click Chemistry and Applications
- vaccines and immunoinformatics approaches
- Vascular Malformations and Hemangiomas
- Orthopedic Surgery and Rehabilitation
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- T-cell and B-cell Immunology
- Mast cells and histamine
Institut Jules Bordet
2014-2024
Université Libre de Bruxelles
2014-2024
Erasmus Hospital
2022
European Institute of Oncology
2009-2012
European Organisation for Research and Treatment of Cancer
2007-2012
Radboud University Nijmegen
2007-2010
Centre Hospitalier Universitaire de Saint-Pierre
1998-2010
Erasmus MC
2007
Yokohama City University
2001
Yokohama City University Hospital
2001
Purpose Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected stage III melanoma in 2011. Here, we present long-term follow-up results this pivotal trial. Patients and Methods In all, 1,256 patients with were randomly assigned to observation (n = 629) or PEG-IFN-α-2b 627) an intended duration 5 years. Stratification factors microscopic (N1) versus macroscopic (N2) nodal involvement, number positive nodes, ulceration tumor thickness, sex, center....
Purpose Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side effects, which necessitates evaluation of health-related quality life (HRQOL). Our trial examined the HRQOL effects pegylated IFN-α-2b (PEG-IFN-α-2b) versus observation patients stage III melanoma. Methods A total 1,256 were randomly assigned after full lymphadenectomy to receive either (n = 629) or PEG-IFN-α-2b 627): induction 6 μg/kg/wk for 8 weeks then maintenance 3 an intended duration 5...
The aim of the present work was to investigate origin and half-life endogenous S100B protein reported by many investigators as a useful melanoma serum marker. Within cells, exists in homo- or heterodimer form containing mainly Ca(++), having substantial fraction bound membranes. As such, is believed be involved regulation cytoskeleton. Also, role cell cycle progression has been suggested. Although appears important intracellular functions, proofs its secretion, at least concentrations such...
Conflicting data have been reported concerning the prognostic value of autoimmune antibodies in patients with melanoma treated adjuvant interferon alfa-2b (IFN). We evaluated significance autoantibodies European Organisation for Research and Treatment Cancer 18991 trial, comparing long-term administration pegylated IFN (PEG-IFN) observation.Anticardiolipin, antithyroglobulin, antinuclear were determined by enzyme-linked immunosorbent assays 296 before random assignment every 6 months after...
BackgroundAppearance of autoantibodies and clinical manifestations autoimmunity in melanoma patients treated with adjuvant interferon (IFN)-α2b was reported to be associated improved prognosis. We assessed the association appearance after initiation treatment recurrence-free interval two randomized trials that compared intermediate doses IFN observation for patients.
Galectin-3 (Gal-3) is a member of the family beta-galactoside-binding mammalian lectins, and has been implicated in tumour invasion metastatic process vitro vivo.To determine whether an increase serum Gal-3 production could be found patients with advanced melanoma.We collected 18 sera from AJCC stage IV melanomas 20 healthy volunteers. Determination was performed by ELISA, group melanoma, these results were compared lactate dehydrogenase (LDH) C-reactive protein (CRP) concentrations.Gal-3...
The etiology of longitudinal melanonychia (LM) is difficult to establish by clinical and dermoscopic examinations alone. Microscopic examination the nail matrix remains crucial. Two groups LM may be identified: melanocytic activation (melanic pigmentation epithelium without any increase in density melanocytes) proliferation (lentigo, nevus, or melanoma). histological challenging, immunohistochemical investigations can helpful. objective this study was analyze findings with routinely used...
Clinical outcome of patients with high-risk melanoma cannot be reliably predicted on the basis classical histopathological examination. Our study aimed to determine in metastases a gene expression profile associated patient survival, and identify validate marker(s) poor clinical outcome. Skin lymph node from (training population) were used candidate prognostic based DNA microarray analysis. Additional skin (validation assess value first ranked by real-time PCR. We performed analysis training...
We previously demonstrated an inverse correlation between tyrosinase-related protein 1 (TYRP1) mRNA expression in melanoma metastases and patient survival. However, TYRP1 was not detected half of tissues expressing did correlate with Based on a study reporting that 3′ untranslated region (UTR) contains two miR-155-5p (named miR-155) binding sites exhibiting single-nucleotide polymorphisms (SNPs) promote (matched miRNA–mRNA interaction) decay or (mismatched), we aimed to investigate the role...
Radiotherapy (RT) in patients with melanoma historically showed suboptimal results, because the disease is often radioresistant due to various mechanisms such as scavenging free radicals by thiols, pigmentary machinery, or enhanced DNA repair. However, radiotherapy has been utilized adjuvant therapy after complete excision of primary and lymph nodes reduce rate nodal recurrences high-risk patients. The resistance cells may also be relation constitutive activation MAPK pathway and/or...
Targeting MAPK pathway in mutant BRAF melanoma with the specific inhibitor vemurafenib showed robust initial responses majority of patients followed by relapses due to acquired resistance drug. In V600EBRAF cell lines, senescence-associated β-galactosidase activity is often encountered a constitutive manner or induced after inhibition. However, link between senescence-like phenotype and inhibition not fully understood yet. Our data validate (low proliferation, high volume, β-Gal activity)...
Clinical outcome of high-risk melanoma patients is not reliably predicted from histopathological analyses primary tumours and often adjusted during disease progression. Our study aimed at extending our previous findings in skin metastases to evaluate the prognostic value tyrosinase-related protein 1 (TYRP1) lymph node stages III IV patients. TYRP1 mRNA expression 104 was quantified by real-time PCR normalised S100 calcium-binding B (S100B) correct for tumour load. TYRP1/S100B ratios were...